Released Nov 7, 2019, before the open
10-Q filed Nov 7, 2019, 38 days after period end · 0001104659-19-060804
Q3 2019 · 10-Q
Revenue$14.25M$14.25M +2,049.0% vs Q3 2018+16.3% vs Q2 2019
Net Income-$3.56M-$3.56M N/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.24-$0.24 N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$1,544,000N/M
Operating Cash Flowderived-$3,225,000N/M
Free Cash Flowderived-$3,617,000N/M
Margins · derived
Operating margin-10.8%+553.4 pt vs Q3 2018
Net margin-25.0%+777.7 pt vs Q3 2018
What the release said
The release
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Revenue | $14.25M | $663.00K | $7.53M | $4.67M |
| Net Income | -$3.56M | -$5.32M | -$11.44M | -$7.29M |
| EPS Diluted | -$0.24 | -$0.40 | -$0.09 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR